The triple-digit million-euro facility is the first worldwide to manufacture industrial-scale quantities of rhamnolipid biosurfactants, which also show huge potential in coatings.
With the sale of its TAA derivatives business to Sabo, Evonik is taking the next step in focusing its portfolio on specialty chemicals.
